18th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy candidate at a leading scientific conference.